AAPL312.47-3.75 (-1.19%) ▼|ABBV249.68+0.90 (+0.36%) ▲|ABT106.46+0.94 (+0.89%) ▲|ACN177.09-1.94 (-1.08%) ▼|ADBE255.63-1.63 (-0.63%) ▼|AMAT465.86-6.93 (-1.47%) ▼|AMD519.99+14.25 (+2.82%) ▲|AMGN392.89-0.29 (-0.07%) ▼|AMT174.71-1.02 (-0.58%) ▼|AMZN251.02-5.95 (-2.32%) ▼|AVGO361.15-7.42 (-2.01%) ▼|AXP322.16-3.94 (-1.21%) ▼|BA209.94-0.79 (-0.37%) ▼|BAC62.77+0.38 (+0.61%) ▲|BKNG172.08-8.22 (-4.56%) ▼|BLK1,079.45-15.92 (-1.45%) ▼|BMY64.41-0.29 (-0.44%) ▼|BNY162.76-0.09 (-0.06%) ▼|BRK-B506.51+0.68 (+0.13%) ▲|C137.89+1.15 (+0.84%) ▲|CAT814.02-8.46 (-1.03%) ▼|CL88.12-0.29 (-0.33%) ▼|CMCSA24.95-1.39 (-5.26%) ▼|COF212.11-1.85 (-0.86%) ▼|COP137.45+2.41 (+1.78%) ▲|COST901.32-8.86 (-0.97%) ▼|CRM249.26+0.14 (+0.05%) ▲|CSCO109.50+0.33 (+0.30%) ▲|CVS95.20-0.87 (-0.91%) ▼|CVX213.22+3.42 (+1.63%) ▲|DE674.49-6.25 (-0.92%) ▼|DHR204.83-0.40 (-0.19%) ▼|DIS104.61-0.45 (-0.43%) ▼|DUK119.88-1.36 (-1.12%) ▼|EMR151.56-0.59 (-0.39%) ▼|FDX310.38-3.75 (-1.19%) ▼|GD353.17-3.41 (-0.96%) ▼|GE323.84-11.07 (-3.31%) ▼|GEV949.41-21.90 (-2.25%) ▼|GILD146.32-0.33 (-0.22%) ▼|GM85.58-0.21 (-0.24%) ▼|GOOG326.97-8.41 (-2.51%) ▼|GOOGL329.44-8.92 (-2.64%) ▼|GS1,027.30-9.24 (-0.89%) ▼|HD311.34-2.37 (-0.75%) ▼|HON205.90-2.34 (-1.12%) ▼|IBM231.14-0.96 (-0.41%) ▼|INTC105.28+0.81 (+0.78%) ▲|INTU315.60-3.33 (-1.04%) ▼|ISRG351.24+1.08 (+0.31%) ▲|JNJ268.77-0.35 (-0.13%) ▼|JPM354.74+1.23 (+0.35%) ▲|KO87.88-0.48 (-0.54%) ▼|LIN464.75-3.64 (-0.78%) ▼|LLY1,128.30+4.39 (+0.39%) ▲|LMT527.30-8.86 (-1.65%) ▼|LOW198.55-2.25 (-1.12%) ▼|LRCX314.07-6.36 (-1.98%) ▼|MA566.33-4.56 (-0.80%) ▼|MCD253.65-2.16 (-0.84%) ▼|MDLZ61.67+0.04 (+0.06%) ▲|MDT92.55+0.16 (+0.17%) ▲|META654.35+40.87 (+6.66%) ▲|MMM165.26-2.26 (-1.35%) ▼|MO67.55-0.62 (-0.91%) ▼|MRK147.48-0.99 (-0.66%) ▼|MS215.27-0.97 (-0.45%) ▼|MSFT492.33-1.62 (-0.33%) ▼|MU1,024.73+24.47 (+2.45%) ▲|NEE82.72-1.11 (-1.32%) ▼|NFLX76.53-0.25 (-0.32%) ▼|NKE37.17-0.93 (-2.44%) ▼|NOW132.52-1.69 (-1.26%) ▼|NVDA224.25-1.49 (-0.66%) ▼|ORCL161.45-1.07 (-0.66%) ▼|PEP136.55-1.90 (-1.37%) ▼|PFE27.91+0.12 (+0.41%) ▲|PG142.84-2.74 (-1.88%) ▼|PLTR171.08+0.78 (+0.46%) ▲|PM183.74-0.99 (-0.54%) ▼|QCOM175.33+1.24 (+0.71%) ▲|RTX198.72-0.09 (-0.05%) ▼|SBUX100.09-1.92 (-1.88%) ▼|SCHW107.54+0.67 (+0.63%) ▲|SO88.25-0.75 (-0.84%) ▼|SPG207.46-2.17 (-1.04%) ▼|T24.98-0.62 (-2.42%) ▼|TMO606.72+3.70 (+0.61%) ▲|TMUS177.44-4.25 (-2.34%) ▼|TSLA369.42+1.26 (+0.34%) ▲|TXN260.57+1.65 (+0.64%) ▲|UBER71.37-1.77 (-2.41%) ▼|UNH390.37-10.47 (-2.61%) ▼|UNP285.44-3.02 (-1.05%) ▼|UPS99.78-0.70 (-0.70%) ▼|USB62.27-0.22 (-0.35%) ▼|V367.01-1.63 (-0.44%) ▼|VZ49.32-1.10 (-2.17%) ▼|WFC89.38+1.42 (+1.61%) ▲|WMT105.84-0.22 (-0.20%) ▼|XOM163.60+2.94 (+1.83%) ▲|AAPL312.47-3.75 (-1.19%) ▼|ABBV249.68+0.90 (+0.36%) ▲|ABT106.46+0.94 (+0.89%) ▲|ACN177.09-1.94 (-1.08%) ▼|ADBE255.63-1.63 (-0.63%) ▼|AMAT465.86-6.93 (-1.47%) ▼|AMD519.99+14.25 (+2.82%) ▲|AMGN392.89-0.29 (-0.07%) ▼|AMT174.71-1.02 (-0.58%) ▼|AMZN251.02-5.95 (-2.32%) ▼|AVGO361.15-7.42 (-2.01%) ▼|AXP322.16-3.94 (-1.21%) ▼|BA209.94-0.79 (-0.37%) ▼|BAC62.77+0.38 (+0.61%) ▲|BKNG172.08-8.22 (-4.56%) ▼|BLK1,079.45-15.92 (-1.45%) ▼|BMY64.41-0.29 (-0.44%) ▼|BNY162.76-0.09 (-0.06%) ▼|BRK-B506.51+0.68 (+0.13%) ▲|C137.89+1.15 (+0.84%) ▲|CAT814.02-8.46 (-1.03%) ▼|CL88.12-0.29 (-0.33%) ▼|CMCSA24.95-1.39 (-5.26%) ▼|COF212.11-1.85 (-0.86%) ▼|COP137.45+2.41 (+1.78%) ▲|COST901.32-8.86 (-0.97%) ▼|CRM249.26+0.14 (+0.05%) ▲|CSCO109.50+0.33 (+0.30%) ▲|CVS95.20-0.87 (-0.91%) ▼|CVX213.22+3.42 (+1.63%) ▲|DE674.49-6.25 (-0.92%) ▼|DHR204.83-0.40 (-0.19%) ▼|DIS104.61-0.45 (-0.43%) ▼|DUK119.88-1.36 (-1.12%) ▼|EMR151.56-0.59 (-0.39%) ▼|FDX310.38-3.75 (-1.19%) ▼|GD353.17-3.41 (-0.96%) ▼|GE323.84-11.07 (-3.31%) ▼|GEV949.41-21.90 (-2.25%) ▼|GILD146.32-0.33 (-0.22%) ▼|GM85.58-0.21 (-0.24%) ▼|GOOG326.97-8.41 (-2.51%) ▼|GOOGL329.44-8.92 (-2.64%) ▼|GS1,027.30-9.24 (-0.89%) ▼|HD311.34-2.37 (-0.75%) ▼|HON205.90-2.34 (-1.12%) ▼|IBM231.14-0.96 (-0.41%) ▼|INTC105.28+0.81 (+0.78%) ▲|INTU315.60-3.33 (-1.04%) ▼|ISRG351.24+1.08 (+0.31%) ▲|JNJ268.77-0.35 (-0.13%) ▼|JPM354.74+1.23 (+0.35%) ▲|KO87.88-0.48 (-0.54%) ▼|LIN464.75-3.64 (-0.78%) ▼|LLY1,128.30+4.39 (+0.39%) ▲|LMT527.30-8.86 (-1.65%) ▼|LOW198.55-2.25 (-1.12%) ▼|LRCX314.07-6.36 (-1.98%) ▼|MA566.33-4.56 (-0.80%) ▼|MCD253.65-2.16 (-0.84%) ▼|MDLZ61.67+0.04 (+0.06%) ▲|MDT92.55+0.16 (+0.17%) ▲|META654.35+40.87 (+6.66%) ▲|MMM165.26-2.26 (-1.35%) ▼|MO67.55-0.62 (-0.91%) ▼|MRK147.48-0.99 (-0.66%) ▼|MS215.27-0.97 (-0.45%) ▼|MSFT492.33-1.62 (-0.33%) ▼|MU1,024.73+24.47 (+2.45%) ▲|NEE82.72-1.11 (-1.32%) ▼|NFLX76.53-0.25 (-0.32%) ▼|NKE37.17-0.93 (-2.44%) ▼|NOW132.52-1.69 (-1.26%) ▼|NVDA224.25-1.49 (-0.66%) ▼|ORCL161.45-1.07 (-0.66%) ▼|PEP136.55-1.90 (-1.37%) ▼|PFE27.91+0.12 (+0.41%) ▲|PG142.84-2.74 (-1.88%) ▼|PLTR171.08+0.78 (+0.46%) ▲|PM183.74-0.99 (-0.54%) ▼|QCOM175.33+1.24 (+0.71%) ▲|RTX198.72-0.09 (-0.05%) ▼|SBUX100.09-1.92 (-1.88%) ▼|SCHW107.54+0.67 (+0.63%) ▲|SO88.25-0.75 (-0.84%) ▼|SPG207.46-2.17 (-1.04%) ▼|T24.98-0.62 (-2.42%) ▼|TMO606.72+3.70 (+0.61%) ▲|TMUS177.44-4.25 (-2.34%) ▼|TSLA369.42+1.26 (+0.34%) ▲|TXN260.57+1.65 (+0.64%) ▲|UBER71.37-1.77 (-2.41%) ▼|UNH390.37-10.47 (-2.61%) ▼|UNP285.44-3.02 (-1.05%) ▼|UPS99.78-0.70 (-0.70%) ▼|USB62.27-0.22 (-0.35%) ▼|V367.01-1.63 (-0.44%) ▼|VZ49.32-1.10 (-2.17%) ▼|WFC89.38+1.42 (+1.61%) ▲|WMT105.84-0.22 (-0.20%) ▼|XOM163.60+2.94 (+1.83%) ▲|
27.1 C
New York
Wednesday, September 9, 2026

Tag: medicines

newssourceFORcompanyinformationcontent1releasesmarket

Neuraxpharm continues international expansion with launch of Neuraxpharm Australia

Avendran Naidu appointed Head of Commercial to lead new affiliate CNS specialist continues growth strategy outside Europe to commercialise CNS treatments, including Nuvigil® (armodafinil), Modavigil®...

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025

CAMBRIDGE, Mass., July 21, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 2025 Alzheimer’s Association International Conference (AAIC), taking place July 27-31 in Toronto, Canada. Data on LEQEMBI® (lecanemab) will include 48-month results from the Clarity AD open-label extension, real-world evidence, and new insights into a subcutaneous formulation for maintenance dosing. Presentations on tau will explore tau-targeted therapies and biomarkers, including baseline characteristics of participants from CELIA, a Phase 2 trial evaluating the efficacy, safety, and tolerability of BIIB080, an investigational antisense oligonucleotide (ASO) therapy that targets tau.

EISAI TO PRESENT FOUR-YEAR EFFICACY AND SAFETY DATA ON CONTINUOUS TREATMENT WITH LECANEMAB AT THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025

Latest findings from Eisai's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-β protofibrils in cerebrospinal fluid,...

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

DUBLIN, July 21, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel’s Board of Directors approved the grant of non-statutory options to six (6) new employees to purchase 34,200 ordinary shares under Avadel’s 2021 Inducement Plan. The awards were granted as an inducement material to the employee’s acceptance of employment with Avadel in accordance with Nasdaq Listing Rule 5635(c)(4). The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of each new employee’s respective start date and 25% vesting on the second, third, and fourth anniversary thereafter. The options are subject to the terms and conditions of Avadel’s 2021 Inducement Plan approved by the Board of Directors in November 2021 and the terms and conditions of award agreements covering the grants.

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

– Alixorexton Demonstrated Clinically Meaningful and Statistically Significant Improvements in Wakefulness at All Doses Tested Compared to Placebo in Patients With Narcolepsy Type 1 – –...

West Welcomes Robert McMahon as Incoming Chief Financial Officer

EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced...

Darolutamide receives EU approval in third indication for patients with advanced prostate cancer

ORION CORPORATION
PRESS RELEASE
21 JULY 2025 at 10:30 EEST          

[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on astegolimab in chronic obstructive pulmonary disease

Basel, 21 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today topline results from the pivotal phase IIb ALIENTO (n=1,301) and the phase III ARNASA (n=1,375) trials investigating astegolimab compared to placebo, on top of standard of care maintenance therapy in people with moderate to very severe chronic obstructive pulmonary disease (COPD). The studies included a broad population: both former and current smokers, regardless of blood eosinophil count, who have a history of frequent exacerbations.

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment.

Duke Energy prepares for potential severe storms in Indiana, urges customers to be ready

PLAINFIELD, Ind., July 18, 2025 /PRNewswire/ -- Duke Energy is monitoring forecasts and preparing for potential severe weather, including strong thunderstorms and damaging winds,...

Zealand Pharma major shareholder announcement: Van Herk Investments B.V.

Company announcement – No. 17 / 2025

EURneffy® (adrenaline nasal spray) Approved in the U.K. as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

EURneffy (neffy® in the U.S.) offers a new delivery method for adrenaline in the U.K. for adults and children (>30 kg) living with severe allergic reactions

Total Investment of Approx. USD 7.3 Million in Malaria and TB R&D Projects With Partners Including European Vaccine Initiative, University of Copenhagen, and University...

TOKYO, July 17, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximately JPY 1 billion (USD 7.3...

Nature Medicine Published Phase 1 Results of Innovent Biologics’ Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma

SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsMedicines

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers